Boothbay Fund Management’s Moderna MRNA Stock Holding History

Boothbay Fund Management’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$974K	Buy	13,906 +6,134	+79%	+$317K	0.01%	1112
2026 Q1	$395K	Buy	+7,772	New	+$363K	0.01%	1476
2025 Q4	–	Sell	-13,542	Closed	-$368K	–	2218
2025 Q3	$350K	Buy	13,542 +4,942	+57%	+$138K	0.01%	1361
2025 Q2	$237K	Buy	+8,600	New	+$226K	﹤0.01%	1189
2024 Q3	–	Sell	-3,250	Closed	-$386K	–	1812
2024 Q2	$386K	Buy	+3,250	New	+$411K	0.01%	1077
2024 Q1	–	Sell	-8,140	Closed	-$810K	–	1806
2023 Q4	$810K	Buy	+8,140	New	+$685K	0.02%	801
2023 Q2	–	Sell	-1,713	Closed	-$263K	–	2109
2023 Q1	$263K	Buy	+1,713	New	+$283K	0.01%	1585
2022 Q4	–	Sell	-2,105	Closed	-$344K	–	2284
2022 Q3	$249K	Buy	2,105 +272	+15%	+$41.3K	0.01%	1661
2022 Q2	$262K	Buy	+1,833	New	+$262K	0.01%	1555
2021 Q3	–	Sell	-1,432	Closed	-$336K	–	2086
2021 Q2	$336K	Buy	+1,432	New	+$256K	0.01%	1216
2021 Q1	–	Sell	-8,850	Closed	-$1.28M	–	1691
2020 Q4	$925K	Buy	+8,850	New	+$895K	0.03%	519
2019 Q1	–	Sell	-15,000	Closed	-$229K	–	835
2018 Q4	$229K	Buy	+15,000	New	+$247K	0.03%	459

Other funds holding MRNA

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Boothbay Fund Management's MRNA Position: Q2 2026 in Review

Boothbay Fund Management increased its Moderna (MRNA) stake by 79% in Q2 2026, buying an estimated $317K and bringing the position to 13,906 shares worth $974K. The position accounts for 0.01% of the portfolio, ranked #1112.

Boothbay Fund Management first reported a position in MRNA in Q4 2018 and has held it in 12 quarters since. 782 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

Boothbay Fund Management held 13,906 shares of Moderna worth $974K as of Q2 2026.
Boothbay Fund Management bought 6,134 Moderna shares in Q2 2026, an estimated $317K.
Moderna made up 0.01% of Boothbay Fund Management's portfolio in Q2 2026, its #1112 holding.
Boothbay Fund Management first reported a position in Moderna in Q4 2018 and has held it in 12 quarters since.
782 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Boothbay Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.